Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Orlando Clinical Research Center

Neither a doctor nor a teaching hospital

Research payments

$21,045,883

1,182 payments

Through program year 2025, Orlando Clinical Research Center is reported as receiving $21,045,883 in research payments, across 1,182 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $3,890,609 252
2024 Research $3,259,827 128
2023 Research $2,026,729 79
2022 Research $2,275,580 147
2021 Research $4,387,036 247
2020 Research $3,037,971 178
2019 Research $2,168,131 151

Breakdown

Who paid Research payments · program years 2019–2025
  1. Incyte Corporation $2,795,999 208 payments
  2. E.R. Squibb & Sons, L.L.C. $2,600,721 20 payments
  3. AstraZeneca UK Limited $1,930,879 14 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $1,849,487 111 payments
  5. Merck Sharp & Dohme Corporation $1,832,940 91 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $1,409,169 90 payments
  7. AbbVie, Inc. $1,056,585 80 payments
  8. Celgene Corporation $1,020,824 18 payments
  9. Vertex Pharmaceuticals Incorporated $782,455 3 payments
  10. BioCryst Pharmaceuticals, Inc. $667,348 39 payments
Studies the money was for Research payments · program years 2019–2025
  1. Single and Multiple Dose Clinical Trial to Study the Safety and Pharmacokinetics of MK-2060 in Older Participants with End-Stage Renal Disease on Hemodialysis $1,278,098 44 payments
  2. A Phase 1, Open-Label, Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Dosing of TAK-861 in Participants With or Without Hepatic Impairment $916,150 17 payments
  3. A Phase 1, Open-label Study to Evaluate the Pharmacokinetics and Safety of Multiple Doses of VX-548 in Subjects With Mild or Moderate Hepatic Impairment and in Matched Healthy Subjects $782,455 3 payments
  4. A Phase I Single-Dose Non-Randomised Open-Label Parallel-Group Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics Safety and Tolerability of AZD0780 $659,732 4 payments
  5. A Phase 1, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis $633,631 24 payments
  6. A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis $595,939 2 payments
  7. A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies $560,868 41 payments
  8. BAY1817080 Liver impairment $546,337 28 payments
  9. A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment $506,231 2 payments
  10. A Phase 1 Study evaluating the Bioavailability of Upadacitinib 45 mg Dose Administered Using Three 15 mg Tablets Relative to one 45 mg Tablet $496,075 11 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record